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Abstract Heparan sulfate (HS), a glycosaminoglycan present
on the surface of cells, has been postulated to have important
roles in driving both normal and pathological physiologies.
The chemical structure and sulfation pattern (domain struc-
ture) of HS is believed to determine its biological function,
to vary across tissue types, and to bemodified in the context of
disease. Characterization of HS requires isolation and purifi-
cation of cell surface HS as a complex mixture. This process
may introduce additional chemical modification of the native
residues. In this study, we describe an approach towards thor-
ough characterization of bovine kidney heparan sulfate
(BKHS) that utilizes a variety of orthogonal analytical tech-
niques (e.g. NMR, IP-RPHPLC, LC-MS). These techniques
are applied to characterize this mixture at various levels in-
cluding composition, fragment level, and overall chain prop-
erties. The combination of these techniques in many instances
provides orthogonal views into the fine structure of HS, and in
other instances provides overlapping / confirmatory informa-
tion from different perspectives. Specifically, this approach
enables quantitative determination of natural and modified
saccharide residues in the HS chains, and identifies unusual
structures. Analysis of partially digested HS chains allows for
a better understanding of the domain structures within this
mixture, and yields specific insights into the non-reducing
end and reducing end structures of the chains. This approach
outlines a useful framework that can be applied to elucidate
HS structure and thereby provides means to advance under-
standing of its biological role and potential involvement
in disease progression. In addition, the techniques de-
scribed here can be applied to characterization of hepa-
rin from different sources.
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Introduction
Heparan sulfate (HS) is a member of the glycosaminoglycan
family, ubiquitously found at the surface of mammalian cells,
where it plays a role in mediating the cell’s interaction with its
extracellular environment. HS is generally present as a proteo-
glycan (HSPG), i.e. covalently attached to a core protein, and
it is involved in different biological processes, including cell-
cell communication, binding of lipoprotein lipases and lipo-
proteins to cell surfaces, regulation of growth factors and cy-
tokines, and binding to antithrombin to support blood flow
across the vascular endothelium [1–5]. HS also has a regula-
tory role in pathological conditions, such as inflammation,
tumor onset, progression, and metastasis [6, 7].
Heparan sulfate is a polydisperse mixture of linear polysac-
charides consisting of repeating units of 1→ 4-linked glucos-
amine and uronic acids that can be variably sulfated during
biosynthesis. Heparan sulfate biosynthesis is a complex pro-
cess that starts with the action of D-glucuronyl and N-acetyl-
D-glucosaminyl transferase to generate a copolymer of alter-
nating HNAc and G, which subsequently undergoes modifica-
tions by at least four families of sulfotransferases and one
epimerase. Enzyme specificity during HS biosynthesis
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dictates the positioning of sulfate groups; also, the expression
levels of different isoforms of HS biosynthetic enzymes con-
tribute to the synthesis of specific saccharide sequences char-
acteristic of each cell type [8].
Despite the significant potential for diversity in HS, the
concerted action of the biosynthetic machinery seemingly
generates putative block structures [9, 10]. In this model, HS
is thought to be composed of NA domains, which are domi-
nated by repeating units of alternating G and HNAc, and
NS domains, constituted of I2S and HNS residues. Mixed
or transition domains that alternate sulfated and non-
sulfated monosaccharides separate the NA domains from
the NS domains [11, 12].
Due to their higher charge density, the NS and transition
domains constitute the preferred protein-binding regions of
HS [13–15]. The major role of the NA domains is to confer
structural flexibility to the HS backbone and facilitate interac-
tion of more sulfated regions of HS with proteins [16]. NA
domains are believed to lack specific binding properties, al-
though heparanases seem to use differences in sulfate content
between NS and NA domains to orient themselves and reach
the sites of cleavage [17].
In addition, specific HS structures and sequences have been
identified as critical for interaction with antithrombin, selectin,
FGF-1 and FGF-2 [18, 19].
Many HS-protein interactions are believed to depend on
the overall organization and spacing of NS domains, which
regulate oligomerization or formation of ternary complexes
[20, 21]. So far, little is known about the distribution of NS
domains along or at the non-reducing end of the HS chains,
while several studies indicate that NA sequences are located
close to the protein-linkage region [22, 23].
A detailed understanding of the structure-function relation-
ship for HS would require elucidation of fine structure, overall
composition, spacing, and distribution of NS, NA, and transi-
tion domains along the HS chain. In this paper, multiple ana-
lytical tools are applied to provide a comprehensive under-
standing of bovine kidney HS (BKHS) structure. First, the
overall disaccharide composition of BKHS is examined and
quantified using orthogonal analytical methods (2D NMR on
intact chains, and enzymatic digestion followed by IP-
RPHPLC and LC-MS). Identification of minor residues such
as epoxide, galacturonic acid, non-sulfated glucosamine, and
glucuronic acid at the non-reducing end of the HS chain is
described in detail.
Next, BKHS is separated into chains of different length to
identify a potential relationship between degrees of polymer-
ization and distribution of NA, NS, and transition domains.
Finally, BKHS is digested with heparinases (Hep) I or III, and
the digested mixture is analyzed by gel permeation
chromatography-mass spectrometry (GPC-MS) to allow char-
acterization of NA, NS, and transition domains both in terms
of chain length and finer structure. The results of GPC-MS,
LC-MS and NMR techniques are used to perform structural
analysis of non-reducing ends and reducing ends of HS
chains, and to identify unusual structures, such as phosphory-
lated residues within the linkage region.
This analysis builds on previous studies that have demon-
strated sequencing of Bsimple^ glycosaminoglycans, such as
bikunin [24], and provides a systematic analysis of the more
structurally complex HS. Given the complexity of HS, em-
ployment of multiple, orthogonal analytical approaches to ob-
tain distinct levels of information on the polysaccharide chain
provides important structural insights in a more comprehen-
sivemanner than is possible from a single analytical approach.
Therefore, this approach outlines a useful framework that can
be applied to elucidate structural properties of a heparan sul-
fate mixture.
Materials and methods
Enzymatic digestion of BKHS samples for IP-RPHPLC
and LC-MS analysis
BKHS (1 mg, Seikagaku) was digested at 30 °C for 16 h using
a cocktail of Bacteroides Heparinases I, III, and IV
manufactured in house. The digested sample was then incu-
bated for 6 h at 30 °C simultaneously with 2-O-sulfatase and
Δ4,5 -glycuronidase. On completion of digestion, the sample
was frozen and lyophilized. Flavobacterium Heparinases (I,
II and III) may also be used instead of the cocktail of
Bacteroides Heparinases I, III, and IV [25].
Ion-pairing reverse phase HPLC analyses
Digested BKHS samples were analyzed by IP-RPHPLC using
30 mM tetra-n-butyl ammonium chloride (TBA) as the ion-
pairing reagent in 15% acetonitrile (ACN). The digested sam-
ples were separated using an analytical C18 Discovery col-
umn (4.6 × 250 mm, Supelco) maintained at 25 °C, with a
flow rate of 0.7 mL/min over 130 min of total run time, with a
gradient ranging from 0 to 1 M NaCl. The elution profile was
monitored by UVabsorption at 232 nm.
LC-MS analysis
Chromatographic separation was performed on a
0.3 mm× 250mmC18 polymeric silica column (thermostated
at 17 °C) at a flow rate of 4 μL/min using a Ultimate 3000
capillary HPLC system (Dionex). The mobile phase consisted
of (A) 8 mM dibutylammonium acetate in 100 % water, (B)
8 mM dibutylammonium acetate in 70 % methanol/30 % wa-
ter and (C) 90% acetonitrile/10 % water. Samples were eluted
with the following step gradient: 0 % B for 4 min, 9 % B for
20 min, 20 % B for 21 min, 32 % B for 19 min, 48 % B for
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17 min, 63 % B for 14 min, 100 % C for 14 min, and 100 %A
for 20 min. To improve ionization, post-column addition of
aqueous methanol was carried out using a secondary binary
solvent system. Mass spectra were acquired in negative mode
with a quadrupole time-of-flight mass spectrometer (Waters-
Micromass, UK). Data acquisition was controlled by
Masslynx 4.1, according to the following settings: source tem-
perature 100 °C, desolvation temperature 200 °C, capillary
voltage 2.4 V, cone voltage 15 V and collision energy 1.7 V.
Size fractionation
10 mg of BKHS were fractionated on a Superdex 75 column
(100 mL column volume) and eluted with 5 mM sodium
phosphate dibasic and 150 mM sodium chloride, pH 7.0, at
a linear flow rate of 15 cm/h. Fractions were buffer-exchanged
with 10 % ethanol using Sephadex G-10 and lyophilized to a
dry powder.
NMR analysis
The mono- and two-dimensional spectra of BKHS were re-
corded at 298 K, with a 600MHzBruker Avance spectrometer
equipped with a 5-mm triple-resonance inverse cryoprobe.
Before spectra acquisition, HS was dissolved at 2 mg/
150 μL of D2O (99.9 %) and sonicated for 30 s to remove
air bubbles.
1H–NMR spectrum was acquired with presaturation of the
residual water signal, with a recycle delay of 5 s, for 64 scans.
COSY spectrum was recorded with presaturation of the water
signal, for 8 scans of 320 increments. TOCSY spectrum was
acquired in phase sensitive mode with 80 ms of DIPSI-2
mixing, for 24 scans of 320 increments. For COSY and
TOCSY spectra, the matrix size was zero filled to 2 K × 2 K
prior to Fourier transformation. HSQC spectrumwas recorded
with sensitivity enhancement and carbon decoupling during
acquisition, for 64 scans of 256 increments. The polarization
transfer delay was set with a 1JC-H coupling value of 155 Hz.
For HSQC spectra, the matrix was zero filled to 2 K × 1 K
prior to Fourier transformation.
GPC-MS analysis
BKHS (0.6 mg) was digested at 30 °C for 16 h with
Bacteroides Heparinases I (5 IU/mg) or III (2 IU/mg). On
completion of digestion, the sample was frozen, lyophilized,
and separated on a chromatographic system consisting of the
Ultimate 3000 with Dual-Ternary Capillary HPLC pumps
(Dionex) and two 4.6 mm × 300 mm, 4 μm gel permeation
TOSOH TSKgel SuperSW2000 columns placed in series and
equilibrated at 25 °C. 100 mM ammonium acetate was used as
eluent at the constant flow-rate of 100 μl/min delivered by
ternary solvent system. The wavelength of the UV detector
(Dionex) was set at 232 nm, followed by the Dionex 2 mm
Anion Self-Regenerating Suppressor 300 (ASRS-300 (2-
mm)) using water as regenerant. Electrolysis of water in the
ASRS-300 was driven by the Dionex SRS controller using the
100 mA current. The flow was post-column controlled by
QuickSplit adjustable flow splitters (Analytical Scientific
Instrument) to a constant splitting ratio of 1:10.
MS analysis was carried out on a quadrapole time-of-flight
(Q-TOF) mass spectrometer (Waters) equipped with an
electrospray ionization source (ESI). Mass spectra were ac-
quired in negative BW″ ion mode; N2 was used as a
desolvation gas as well as a nebulizer. Conditions for ESI-
MS were as follows: source temperature 100 °C, desolvation
temperature 300 °C, capillary voltage 2.4 kV, desolvation gas
flow 250 L/h, cone voltage 7 V, cone gas flow 100 L/lr, and
collision energy set to 1.2 V. MS spectra were generated by
scanning the range of m/z 70–1400, scan time 1.0 s, interscan
time 0.1 s. and pusher cycle time 99 μs.
Digestion with alkaline phosphatase
HS (200 μg), previously digested with Bacteroides
Heparinase III, was diluted in 1 mL of 50 mM Tris, pH 8.8,
containing 1 mM MgCl2. Six units of alkaline phosphatase
(from E coli, Sigma-Aldrich) were added and the solution
was incubated at 37 °C overnight.
Results
Composition analysis by IP-RPHPLC, NMR, and LC-MS
In this study, ion-pairing reverse phase high performance liq-
uid chromatography (IP-RPHPLC) was used to determine di-
saccharide composition of BKHS after exhaustive digestion
with a cocktail of heparinases, as reported previously. Peaks
were identified by co-injection with commercial standards, or
through peak isolation and characterization bymass spectrom-
etry (MS) and nuclear magnetic resonance spectroscopy
(NMR). The disaccharide composition of BKHS is reported
in Table 1. Consistent with characterization of HS from other
sources [26], IP-RPHPLC data indicate that six disaccharides
constitute more than 90 % of BKHS (based on area percent-
age): ΔUHNAc, ΔUHNS, ΔUHNAc6S, ΔUHNS6S, ΔU2SHNS,
and ΔU2SHNS6S where ΔU indicates the formation of a Δ
4,5
glycuronidate as a result of enzymatic cleavage. A
tetrasaccharide corresponding to the anti-thrombin binding
site, i.e. ΔUHNAc6SGHNS3S6S [27], was also identified. As
previously demonstrated, this structure is resistant to further
enzymatic cleavage due to the presence of a reducing glucos-
amine carrying a sulfate group at the 3-O position [28].
To complement and extend results obtained by IP-
RPHPLC, intact BKHS was analyzed by mono- and di-
dimensional NMR. 1H–NMR and 1H-13C heteronuclear
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single quantum coherence (HSQC) spectra of BKHS are re-
ported in Fig. 1a, b, respectively. Assignment of HSQC cross
peaks was based on literature data [29, 30] and analysis of
COSY, TOCSY, and ROESY spectra (data not shown).
Taken together, the NMR data identify HNS-(I2S/I) and HNS/
NAc-(G) as the major glucosamine components of BKHS, and
HNS3S, HNH2, and (HNAcαred) as minor glucosamine compo-
nents (Table 2). The most prevalent uronic acids include
I2S-(HNS), I-(HNS/NAc), and G-(HNS/NAc). Although most of
these residues are identified by the chemical shifts of H1/C1,
the position of the H2/C2 peaks allows discrimination be-
tween I2S-(HNS6OH) and I2S-(HNS6S) (4.349/77.32 and 4.341/
78.72 ppm, respectively) [31]. The presence of small amount
of epoxide is indicated by a weak signal at 5.41/97.1 ppm.
Epoxide is an unnatural residue, generated by the basic re-
agents used during isolation of HS from the protein core.
Treatment with bases is known to cause 2-O-desulfation of
uronic acids with concomitant formation of epoxide [32].
Besides mono/disaccharide composition, NMR analysis
provides useful information regarding the non-reducing and
reducing end of BKHS chains. Glucuronic acid located at the
non-reducing end is differentiated from internal glucuronic
acid by the distinct chemical shift of its H3/C3 and H4/
C4 signals. While peaks corresponding to internal glucu-
ronic acid resonate at 3.73/79.2 and 3.83/79.5 ppm in a
spectral region crowded with signals, non-reducing glu-
curonic acid exhibits clear resonances at 3.55/77.9 (H4/
C4) and 3.53/74.7 ppm (H3/C3) [33].
Signals of monosaccharides belonging to the linkage re-
gion are observed at 4.67/106.8 ppm (GlcA-β1–3- and
Gal-β1–3-) and 4.55/104.1 ppm (Gal-β1–4-). The presence
of a xylose residue is indicated by H5,5′/C5 cross-peaks at
3.42/65.8 and 4.10/65.8 ppm. Signals at 5.22/94.8 ppm and
4.62/99.3 ppm are assigned to the H1/C1 of the α and β form
of xylose, respectively, which is present as a reducing sugar.
This observation suggests that the conditions commercially
used to isolate BKHS release the saccharide chain from the
Ser residue of the proteoglycan core. Additional signals at
5.23/93.4 ppm and 6.37/98.9 ppm are attributed to reducing
N-acetyl glucosamine (α and β, respectively), providing evi-
dence of the presence of BKHS chains lacking the linkage
region sequence. Quantitative composition analysis is per-
formed by integrating the relevant peaks in the HSQC spec-
trum of BKHS (Table 2). The amount of linkage region andN-
acetyl glucosamine at the reducing position is used to estimate
an average chain length of 16 disaccharides. The rela-
tive amount of glucuronic acid at the non-reducing end
of the chains is comparable to the amount of reducing
end residues (i.e., linkage region plus HNAc redox), in-
dicating that in commercial BKHS the majority of the
chains start with a G residue.
The monosaccharide composition determined either by IP-
RPHPLC and 2D NMR is compared in Supplementary
Table 1. Although IP-RPHPLC analysis has the advantage
of requiring less material compared to NMR, the latter pro-
vides additional structural information, including
epimerization at the C5 position of the uronic acid within
different disaccharide moieties. In addition, unlike IP-
RPHPLC, 2D NMR detects residues lacking UVabsorbance,
e.g., glucuronic acid present at the non-reducing end of chains.
Finally, NMR is better suited to characterize the linkage re-
gion and to determine the presence of residual serine, oxidized
serine, or the lack of it. Identification by HPLC is in this case
hampered by the lack of suitable standards and by the fact that
the current HPLC conditions are optimized to separate sulfat-
ed disaccharides and, consequently, are not efficient in isolat-
ing neutral residues like the linkage region. This is also the
reason why, although NMR shows presence of small amounts
of unsubstituted glucosamine (HNH2), such a residue could not
be detected by IP-RPHPLC (the standard ΔUHNH2 elutes in
the void volume).
Analysis of IP-RPHPLC and NMR data indicates general
agreement between the two techniques regarding sulfation
level and overall composition. However, IP-RPHPLC analy-
sis shows presence of galacturonic acid (ΔUgal), while NMR
detects 2,3-epoxide [34]. The root cause for this apparent dis-
crepancy could be attributed to the use of heparin lyase en-
zymes prior to HPLC analysis, which may result initially in
hydrolysis of the epoxide to galacturonic acid, then in conver-
sion of galacturonic acid toΔUgal through H5 abstraction and
glycosidic bond cleavage. Preliminary experiments performed
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with various enzyme cocktails seem to confirm this hypothe-
sis (data not shown).
To detect structures present in trace amounts, and complete
compositional analysis of BKHS, a LC-MS method based on
ion-pairing reversed phase high performance liquid chroma-
tography (IP-RPHPLC) coupled to electrospray ionization
time-of-flight mass spectrometry (ESI-TOF-MS) was applied
to BKHS digested with heparin lyases. This analysis con-
firmed the major constituents previously detected by IP-
RPHPLC (see Supplementary Table 2). Furthermore, the
higher degree of sensitivity of ESI-MS enabled identification
of additional species below the detection limit of IP-RPHPLC,
e.g., unsaturated tetrasaccharides with different levels of
sulfation and acetylation. These tetrasaccharides contain a 3-
O-sulfated glucosamine or an epoxide moiety, which explains
their resistance to complete enzymatic digestion. Although
epoxide residues may be converted into galacturonic acid by
heparinases, trace amounts can be detected by ESI-MS.
Importantly, through the detection of disaccharides that do
not contain a Δ4,5 glycuronate, LC-MS analysis provides
information regarding the non-reducing end of chains. Two
types of non-reducing end structures are identified: saturated
trisaccharides starting with a glucosamine residue and saturat-
ed di/tetrasaccharides starting with an uronic acid moiety.
These saccharides present different levels of acetylation and
sulfation, ranging from zero to three sulfates per disaccharide
and from two to five sulfates per trisaccharide. A fragment
present at the reducing end of the chain is also identified, i.e.
ΔU-Gal-Gal-Xyl-OH. A molecular mass of 337.10 Da
assigned to the building block ΔUHNH2 provides evidence of
the presence of unsubstituted glucosamine, as previously
shown by 2D NMR data.
Size fractionation To determine whether disaccharide com-
position changes as a function of chain length, BKHS was
separated by SEC into seven fractions with different elution
times. These fractions were then digested with a heparinase
cocktail and analyzed by IP-RPHPLC (Table 3). Disaccharide
composition data indicate that shorter chains contain a higher
























Fig. 1 a 1H–NMR and b HSQC
spectra of BKHS. Signals due to
the reducing end (xyl α/β and
HNAc α), non-reducing end (G
n.r.), and differently substituted
internal I2S are indicated
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in ΔUHNAc) as well as residues attributed to the NS region
(i.e.ΔU2SHNS6S andΔU2SHNS). Shorter chains contain fewer
residues of the transition regions, as indicated by lower levels
of ΔUHNS, ΔUHNS6S, and ΔUHNAc6S. Comparison of N-
sulfation, 6-O-sulfation, and 2-O-sulfation levels among
chains of different length indicates that shorter chains contain
less 6-O and N-sulfates than longer chains, but are more sul-
fated at the 2-O position (Table 4).
GPC and GPC-MS analysis of HS digested with HepI or
HepIII To examine chain composition in finer detail, BKHS
was initially digested with either Hep I, an enzyme that
cleaves highly sulfated regions, or Hep III, which cleaves N-
acetylated and undersulfated domains [36, 37]. After over-
night digestion, reaction products were separated by GPC
and the UVelution profile at 232 nm was integrated to deter-
mine the fragments composition and length distribution
(Supplementary Figs. 1 and 2, Supplementary Tables 3
and 4). Digestion of BKHS with Hep I degrades NS domains
into disaccharides while substantially preserving the NA and
the transition domains of the BKHS chains. GPC of Hep I-
digested BKHS indicates that fragments containing 20 or
more monosaccharides represent a significant portion of this
sample. Conversely, digestion of BKHSwithHep III provides
mainly disaccharides; tetra- to dodeca-saccharides constitute
in this case a small portion of the total mixture.
Fragments generated by Hep I and Hep III digestion were
consequently analyzed by GPC-MS (Supplementary Tables 5
and 6, respectively). The relative abundance of each fragment
was derived from peak intensities determined by applying the
MaxEnt3 (MaximumEntropy) algorithm and after application
of correction factors to selected residues (see Supplementary
Information). Correction factors are introduced to compensate
for variations in ionization efficiency of saccharides contain-
ing different molar quanti t ies of sulfate groups.
Table 2 Relative percentage of variously substituted glucosamine and
uronic acid in BKHS determined by HSQC analysis






























1 Residues reported in brackets indicate the monosaccharide downstream
of the quantified glucosamine or uronic acid residue
2Mole % of the total glucosamine content
3 X = S or Ac
4Mole % of the total uronic acid content
5 The amount of G at the non-reducing end is calculated as 6.4 % of the
total uronic acid content
Table 3 IP-RPHPLC analysis of
BKHS and its fractions (Rel. Area
%). Fractions are reported in order
of elution: Pool 1 + 2 corresponds
to the fraction with the highest
MW, Pool 10 to the fraction with
the lowest MW. The MW
progressively decreases form

















ΔUHNAc NA domain 55.2 52.0 53.5 53.5 54.3 56.4 58.1 58.1
ΔUHNS Transition 17.7 20.1 19.5 19.0 18.3 17.3 16.4 15.9
ΔUHNAc6S
1 Transition 10.3 12.0 12.0 11.0 10.6 9.2 8.9 7.9
ΔUHNS6S Transition 6.1 6.9 6.0 6.3 6.3 6.1 5.6 6.0
ΔU2SHNS NS domain 6.1 4.6 4.8 5.6 5.9 6.2 6.4 6.9
ΔU2SHNS6S NS domain 4.6 4.4 4.2 4.5 4.5 4.8 4.6 5.2
1Glucosamine 6-O-sulfotransferase sulfates HNAc residues provided that there is a HNS residue on either the
upstream or the downstream disaccharides [35]. According to the enzyme specificity, we can assume that all
the ΔUHNAc6S residues are in the transition region or just at the border of it
2 The relative standard deviation (RSD) for the peaks measured by this method is ≤1 %, which basically
corresponds to a change in peak area of ±0.6 for the most abundant peak and about ±0.1 or less for the lower
abundance peaks. Therefore, the changes observed across fractions are larger than what would be expected by
method variability
112 Glycoconj J (2017) 34:107–117
Experimentally, using isolated saccharide standards, it was
established that differences in ionization due to sulfation are
more significant for shorter fragments (i.e., disaccharides).
Given this result, it was considered more robust to base disac-
charide quantification on UVabsorbance; therefore, the disac-
charide ratio determined by MS was adjusted to reflect abun-
dances determined by UV. The same correction factors were
applied to both saturated and unsaturated disaccharides.
Fragments listed in Supplementary Tables 5 and 6 can be
traced back to their position within the BKHS chains: saturat-
ed residues derive from the non-reducing end of the chain;
residues with aΔ4,5 moiety are originally internal to the chain;
residues of formula ΔU-Gal-Gal-Xyl-OH belong to the link-
age region at the reducing end of the chain. Monosaccharides
and residues of formula H-(U-H)n are believed to derive from
the non-reducing end of the chain. As will be described below,
digestion of HS followed by GPC-MS analysis is a useful tool
to provide information regarding the NS, NA, and transition
domains internal to the chain, as well as the non-reducing and
reducing ends of the chain.
Characterization of transition and NA domains Digestion
with Hep I largely preserves NA domains and transition do-
mains, while it hydrolyzes NS domains to component disac-
charides. The GPC profile of BKHS digested with Hep I in-
dicates that fragments with a degree of polymerization (Dp)
from 8 to 20 are approximately equally represented, and
chains longer than Dp20 constitute about 20 % of the entire
mixture. Because NA domains are defined as repeating units
of G-HNAc residues, fragments generated by Hep I can be
undoubtedly classified as belonging to NA if they contain a
number of acetyl groups equal to (Dp-N)/2 and at least two
sulfated residues, which supposedly reside at the border of the
NA region and constitute the site of action of Hep I. Residues
that are assigned to NA domains are marked with an asterisk
in Supplementary Table 5. The presence of fragments with a
Dp ≥ 20 indicates that BKHS contains NA domains longer
than 18 saccharides. Fragments that possess a number of ace-
tyl groups ≤ (Dp-N)/2 are assigned to the transition regions.
Transition regions are characterized by significantly higher 2-
O sulfation and/or 6-O sulfation than NA domains, as demon-
strated by the presence of structures of formula
Dp20,Ac7,S8,Δ and Dp18,Ac7,S6,Δ. Interestingly, the
transition domains appear to be of comparable length to the
NA domains.
Characterization of NS domains By preserving sulfated
regions, digestion of BKHS with Hep III allows character-
ization of NS domains (Supplementary Table 6). The max-
imum length of fragments obtained after digestion with
Hep III is Dp12, providing evidence that within BKHS
the NS domains are significantly shorter than the NA or
the transition domains. The number of sulfate groups per
fragment of the same length indicates that 6-O-sulfation is
highly variable: some fragments are completely 6-O-sulfat-
ed (e.g., Dp8,10S,0Ac,Δ) whereas others are 6-
O-desulfated (e.g., Dp8,7S,0Ac,Δ). Interestingly, shorter
fragments (Dp ≤8) are more likely to present acetyl groups
at the border of the NS domains.
Characterization of non-reducing end Characterization of
BKHS non-reducing ends is performed by GPC-MS analysis
of saturated residues obtained after digestion of BKHS with
Hep I and Hep III (Supplementary Tables 5 and 6,
respectively). It was previously reported that non-reducing
ends of HS chains are mainly sulfated [38]. The GPC-MS
and HSQC data reported here indicate that they also contain
N-acetylglucosamine in significant amounts, and that the most
abundant residue observed at the non-reducing end of BKHS
chains is glucuronic acid (G). Despite the presence of N-
acetylglucosamine, non-reducing ends do not contain NA do-
mains, but NS sequences ranging from 8-mer to 12-mer, or
transition domains up to 8-mer. Although complete structural
elucidation goes beyond the MS capabilities of this experi-
mental set-up, assignment of the predominant non-reducing
end structures is proposed by combining information derived
from GPC-MS, NMR, the known substrate specificities of
Hep I and Hep III [36, 37], and observations from previous
studies on the biosynthetic machinery of HS. Given this set of
information, assignment of the non-reducing end structures is
proposed in Tables 5 and 6.
Characterization of reducing end Confirming NMR data,
LC-MS and GPC-MS identify ΔU/G-Gal-Gal-Xyl-OH as
the most abundant residue attributed to the linkage region
(Supplementary Table 6). A residue of mass 712.14 Da, cor-
responding to the mass ofΔU-Gal-Gal-Xyl-OH plus 80 mass
Table 4 Relative percentage of
N-sulfation vsN-acetylation, 6-O-
sulfation, and 2-O-sulfation in
BKHS and its fractions (IP-
RPHPLC data). Fractions are
reported in order of elution: the
MW progressively decreases
form Pool 1 + 2 to Pool 10
Intact Pool 1+ 2 Pool 3 Pool 4 Pool 5 Pool 7 Pool 8 Pool 10
N-Sulfation 34 37 35 36 36 34 33 33
N-Acetylation 66 64 66 64 65 66 67 66
6-O-Sulfation 21 24 22 22 22 20 19 19
2-O-Sulfation 11 9 9 10 10 11 11 12
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units is also observed in BKHS digested with Hep III. To
determine whether the 80 mass units could be attributed to a
phosphate (PO3
−) or to a sulfate (SO3
−) group, the sample was
digested with alkaline phosphatase and analyzed byGPC-MS.
Disappearance of the peak atm/z 711.14 [M-H]− and concom-
itant increase of the peak at m/z 631.21 [M-H]− provided
evidence of the presence of a phosphorylated residue.
Fragmentation analysis showed that the phosphate group is
carried by xylose (data not shown). Interestingly, the presence
of phosphorylated linkage region has been previously report-
ed only in bovine lung HS [39]. Phosphorylated linkage re-
gion is present only in one of the two commercial lots of
BKHS analyzed. This may indicate that the amount of phos-
phate is highly variable, or that the isolation procedure may
not consistently preserve these structures.
No residues containing the linkage region were observed
by GPC-MS analysis of BKHS digested withHep I. Based on
this analysis, the disaccharide sequences close to the linkage
region are believed to be mainly non-sulfated, and therefore
not easily degraded by Hep I. The linkage region may be
present in long fragments not easily detectable by GPC-MS
analysis [40].
Discussion
Elucidation of GAG chain sequences is a challenging task due
to the inherent variability imparted by a non-template driven
biosynthetic process coupled with the difficulty of isolating
individual HS chains for structural characterization. The the-
ory that GAGs may possess a unique sequence is a subject of
considerable debate. Although it is known that biosynthetic
enzymes are responsible for organizing HS chains into regions
of high sulfation separated by domains of low sulfation [41], it
is still unclear whether they possess enough specificity to ar-
range such domains according to a specific pattern. Recent
studies conducted on bikunin GAG indicate that this
simple proteoglycan possesses a defined sequence [24]:
because different members of the glycosaminoglycan
family share a common biosynthetic pathway, results
obtained on bikunin GAGs seem to suggest that other
GAGs could have well-defined sequences.
To provide additional characterization of HS and to devel-
op a protocol for analysis of complex polysaccharide mix-
tures, orthogonal analytical methods were optimized and ap-
plied to BKHS structural elucidation. The initial efforts fo-
cused on implementation of orthogonal analytical methods
to determine the fine structure of BKHS, i.e., its mono
Table 5 GPC-MS Analysis of
non-reducing end residues of
BKHS digested by Hep I
Composition Relative intensity Proposed Sequence
Dp2, Ac0, S1, saturated 1.14 G-HNS
Dp2, Ac0, S2, saturated 2.48 G-HNS6S
Dp4, Ac1, S2, saturated 0.94 G-HNAc-G
1-HNS6S
Dp4, Ac0, S3, saturated 0.42 G-HNS6X–G/I-HNS6X
Dp4, Ac1, S3, saturated 0.38 G-HNAc6S–G
1-HNS6S
Dp4, Ac0, S4, saturated 0.17 G-HNS6S–G/I-HNS6S
Dp6, Ac1, S3, saturated 0.13 G-HNAc6X
2,3-G1-HNS6X
2,3-G/I-HNS6X
Dp6, Ac1, S4, saturated 0.09 G-HNAc6X
2,3-G1-HNS6S
2,3-G/I-HNS6S
Dp6, Ac2, S2, saturated 0.10 G-HNAc-G
1-HNAc6X
2-G-HNS6X
Dp8, Ac2, S4, saturated 0.02 Not determined
X = S or OH
1 The specificity of the enzymes that synthesize HS suggests that immediately downstream fromHNAc there must
be a G [51]. Exception have been found, but these structures should constitute a minority
2 Glucosamine 6-O-sulfotransferase sulfates HNAc residues provided that there is a HNS residue on either the
upstream or the downstream disaccharides
3 the positions of HNAc and HNS,6X can be interchanged
Table 6 GPC-MS Analysis of non-reducing end residues of HS
digested by Hep III
Composition Relative intensity Proposed Sequence
Dp2, 0S, 1Ac, saturated 0.83 G-HNAc
Dp2, 2S, 0Ac, saturated 0.25 G-HNS6S
Dp8, 6S, 2Ac, saturated 0.11 Not determined
Dp8, 7S, 0Ac, saturated 0.14 G-(HNS-I2S)3-HNS
Dp8, 8S, 0Ac, saturated 0.21 G-(HNS6X–I2S)3-HNS6X
Dp8, 9S, 0Ac, saturated 0.12 G-(HNS6X–I2S)3-HNS6X
Dp8, 10S, 0Ac, saturated 0.07 G-(HNS6S–I2S)3-HNS
Dp10, 9S, 0Ac, saturated 0.07 G-(HNS-I2S)4-HNS
Dp10, 10S, 0Ac, saturated 0.09 G-(HNS6X–I2S)4-HNS6X
Dp10, 11S, 0Ac, saturated 0.04 G-(HNS6X–I2S)4-HNS6X
Dp12, 11S, 0Ac, saturated 0.02 G-(HNS-I2S)5-HNS
Dp12, 12S, 0Ac, saturated 0.02 G-(HNS6X–I2S)5-HNS6X
X = S or OH
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−/disaccharide composition. Three different techniques were
evaluated: 2D NMR HSQC analysis of intact BKHS, and IP-
RPHPLC and LC-MS analysis of BKHS digestedwith a cock-
tail of heparinases. By detecting major components as well as
structures present in small amount such as HNH2, HNS3S,
ΔU2SHNAc6X, or ΔUHNAc6SGHNS3S6X, HSQC and IP-
RPHLC provide a snapshot of the structural microheterogene-
ity of BKHS. These techniques also identify unnatural moie-
ties generated by the chemical treatment used to release HS
from the proteoglycan core, i.e. 2,3-epoxide and GalA,
allowing control over the extent of modification caused by
the isolation process [32]. HSQC and IP-RPHLC methods
can easily be applied to determine sulfation levels at specific
positions (i.e., at the 2-O position of uronic acids, or at the N-
and 6-O position of glucosamine residues), making them suit-
able techniques to compare HS from different sources or path-
ologic states [42, 43]. In addition, detailed monosaccharide
analysis could provide insight into the post-biosynthetic fate
of BKHS: the presence of significant amount of glucuronic
acid at the non-reducing end of the chains rules out extensive
digestion by β-D-glucuronidase or heparanase, enzymes that
would generate chains starting with a glucosamine residue.
LC-MS analysis of HS chains digested with a cocktail of
heparinases is a valuable technique to detect structures that are
present in trace amount, below the limit of detection for NMR
and IP-RPHPLC. When applied to the study of non-reducing
end structures, LC-MS identifies free glucosamine (HNH2) and
saturated trisaccharides starting with a glucosamine residue, in
addition to saturated di/tetrasaccharides starting with a uronic
acid moiety. The presence of saturated residues with different
grade of sulfation indicates that non-reducing ends possess a
highly variable composition. A recently developed analytical
approach based on LC-MS analysis of non-reducing ends of
enzymatically digested GAGs isolated from cells, blood and
urine is intended to be used as a diagnostic tool to detect
lysosomal enzyme deficiency [44].
IP-RPHPLC analysis of BKHS fractionated according to
chain length suggests that disaccharide composition, as well
as domains organization, change as a function of chain poly-
merization. Shorter chains seem to contain higher relative
amount of disaccharides belonging to the NA and NS regions,
and less residues belonging to the transition regions. Previous
reports indicated that 2-O and 6-O-sulfotransferase enzymes
are independently regulated during HS biosynthesis [45].
Currently, a comparison of 6-O-sulfation, 2-O-sulfation, and
N-sulfation levels among chains of different length suggests
that N-deacetylases, N-sulfotranferases, and 6-O-
sulfotransferases are more active on longer chains, while 2-
O-sulfotranferases modify shorter chains more extensively
than longer chains. It was previously acknowledged that
chains of different lengths may have different composition,
and that chain length may be indicative of different biological
roles of HS: neuroepithelial cells secrete shorter and simpler
chains when they interact with FGF-2, and longer and more
complex chains when they interact with FGF-1 [46].
To determine length, distribution, and composition of dif-
ferent domains, BKHS is digested with eitherHep I orHep III,
and the obtainedmixtures are analyzed byGPC andGPC-MS.
Digestion with Hep I, an enzyme that preserves non-sulfated
sequences, provides fragments with a degree of depolymeri-
zation ranging from 2 to more than 20 saccharides, which can
be assigned by MS to either NA or transition domains. Taken
together, MS data, degree of polymerization, and acetylation/
sulfation levels of fragments obtained by Hep I digestion sug-
gest substantial structural diversity within BKHS. These re-
sults seem inconsistent with the hypothesis that commercially
available BKHS possesses well defined sequences, although
this may hold true for chains isolated from a single glycosyl-
ation site in specific cells. NS domains obtained after diges-
tion of BKHS with Hep III present a maximum length of 12
saccharides, and show variable degrees of sulfation. Overall,
the results indicate that in BKHS, NS domains are shorter,
while NA and transition domains are longer and of compara-
ble length. Analysis of saturated fragments obtained by Hep I
or Hep III digestion shows that non-reducing ends of BKHS
contain NS sequences ranging from 8-mer to 12-mer, or tran-
sition domains up to 8-mer long. Although quantitative GPC-
MS analysis indicates that non-reducing ends contain N-
acetylglucosamine in significant amounts, no extended NA
domains are detected. The longest NS domain identified at
the non-reducing end of BKHS is a dodecasaccharide [47],
which is also the maximum length of the NS domains ob-
served within the BKHS chain.
Differently from non-reducing ends, which are constituted
by NS or transition domains, reducing ends of BKHS are
believed to contain mainly NA domains [48]. In support of
this conclusionGPC-MS analysis of BKHS digestedwithHep
III shows fragments belonging to the linkage region, indicat-
ing that such residues are most likely immediately preceded
by non-sulfated disaccharides. GPC-MS also reveals
traces of linkage region fragment where xylose carries
a phosphate group. To our knowledge, although phos-
phorylated linkage region was previously observed in
bovine lung HS [39], this is the first report of the pres-
ence of phosphate groups in BKHS.
Implementation of orthogonal analytical techniques, such
as outlined here, provides a coherent strategy to address HS
structure, even in the context of a mixture of chains.
Furthermore, we have demonstrated in a separate study (re-
cently published in Scientific Reports [49]) howmathematical
modeling can be applied to orthogonal analytical measure-
ments, like those described here, to estimate mixture proper-
ties of a complex mixture like heparan sulfate. Combined with
structural tools, including array technologies, analysis of HS
topology, as well as analysis of HS-protein interactions
through crystallography [50] and NMR [51], the ability to
Glycoconj J (2017) 34:107–117 115
elucidate more general structure-activity relationships for this
class of molecules should be increased substantially by the
application of such an approach.
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